

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Acotec Scientific Holdings Limited**

**先瑞達醫療科技控股有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 6669)**

### **VOLUNTARY ANNOUNCEMENT**

#### **EXPANSION OF SCIENTIFIC ADVISORY BOARD AND APPOINTMENT OF PRINCIPAL INVESTIGATORS FOR ACOART BTK GLOBAL IDE STUDY**

On October 8, 2021, Acotec Scientific Holdings Limited (the “**Company**”) has expanded its Scientific Advisory Board (the “**Scientific Advisory Board**”) by inviting four more top physicians, Prof. Peter Schneider, Dr. Matthew T. Menard, Dr. Sahil A. Parikh, and Prof. Thomas Zeller to join. The Scientific Advisory Board will provide guidance to and lead the execution of the Company’s global study for below-the-knee (BTK) drug-coated balloons (DCB) products indication expansion in the U.S. and Europe (“**AcoArt BTK Global IDE Study**”) for the purpose of registration with U.S. Food and Drug Administration (FDA) in the U.S. Meanwhile, the Scientific Advisory Board will also provide input and feedback to guide the Company’s new product development in peripheral intervention space and will support the Company’s physician education both in China and in global market.

The Company’s BTK DCB product has been granted the Breakthrough Device Designation in 2019 by FDA and is the first DCB product that gets approved based on positive multi-center randomized controlled clinical trial (RCT) data. Breakthrough Device Designation from FDA makes the Company’s BTK DCB product eligible for an expedited assessment and review process and be enrolled into U.S. Medicare coverage on the date of FDA market authorization. AcoArt BTK Global IDE Study will be led by the co-principle investigators including Dr. Matthew T. Menard, Dr. Sahil A. Parikh and Prof. Thomas Zeller.

Dr. Matthew T. Menard is a Castle Connolly Top Doctor whose specialty is vascular surgery and is located in Boston, MA. He is the director of the vascular and endovascular fellowship program and co-director of the Endovascular Surgery Program at Brigham and Women’s Hospital’s (BWH). He is a vascular and endovascular surgeon at BWH and an assistant professor of surgery at Harvard Medical School (HMS). Dr. Matthew T. Menard is also the co-principal investigator for Best Endovascular vs. Best Surgical Therapy in Patients with Critical Limb Ischemia (BEST-CLI), which is an international research study aimed at figuring out the best treatment for people with peripheral arterial disease (PAD) and associated with Critical Limb Ischemia (CLI). BEST-CLI is Federally funded by the National Heart, Lung and Blood Institute at the National Institutes of Health of U.S.

Dr. Sahil A. Parikh is the Director of Endovascular Services at Columbia University Irving Medical Center and Associate Professor of Medicine at the Columbia University College of Physicians and Surgeons in New York City. Dr. Sahil A. Parikh has an active practice in cardiovascular medicine with a focus on atherosclerotic vascular disease and intervention throughout the circulation. He has won a number of teaching awards locally and co-directs several national educational programs for physicians in training and for continuing medical education in conjunction with the Cardiovascular Research Foundation, the American College of Cardiology, and the Society for Cardiovascular Angiography and Interventions. He has been the site and national principal investigator for several clinical trials and has authored more than 50 original manuscripts and reviews in basic and clinical cardiovascular medicine.

Prof. Thomas Zeller is the Head of the Department of Angiology at the University Heart Center Freiburg/Bad Krozingen in Germany. He is an internationally recognized expert in endovascular interventions with a research focus on the development and testing of new interventional technologies for complex endovascular interventions. He has been principle investigator of numerous clinical trials including several studies on DCB technologies such as Thunder and the In.Pact series of clinical projects leading to US approval of Medtronic's IN. PACT Admiral DCB in femoropopliteal arteries.

The co-principle investigators will be supported by the Scientific Advisory Board led by Prof. Dierk Scheinert and Dr. Peter Schneider, both being well recognized international experts in the field of endovascular interventions with track record in the field of new device developments.

Prof. Dierk Scheinert is an interventional cardiologist and angiologist and a worldwide leader in peripheral intervention. He has published extensively and is a sought-after lecturer on his primary research focus, the minimally invasive treatment of arteriosclerosis and other cardiovascular conditions. He is the Medical Director University Hospital Leipzig and Head Center for Vascular Medicine, Angiology and Vascular Surgery. He is recognized internationally for his expertise in both coronary and peripheral vascular interventions. Prof. Dierk Scheinert is a co-founder of the Leipzig Interventional Course (LINC) and has served as its director since 2005. Since 2005, he is also the chairman of the Vascular Center of Park Hospital Leipzig, where he has developed an international referral center for the multidisciplinary and multimodality management of arterial disease. Since September 2015, he is Chairman of the Division of Interventional Angiology at the University hospital in Leipzig. Prof. Dierk Scheinert has authored more than 100 articles in peer-reviewed medical journals and frequently serves as faculty for major medical congresses. He is also a member of the medical and scientific advisory boards of several medical device companies.

Dr. Peter Schneider is Professor of Surgery in the Division of Vascular & Endovascular Surgery at University of California San Francisco. Dr. Schneider has served on a number of committees for the Society for Vascular Surgery and is the past president of Western Vascular Society where he also served on a number of its committees. He is the co-director and steering committee member of Vascular Interventional Advances (VIVA), one of the largest annual multidisciplinary vascular education conference for physicians and healthcare professionals in the U.S. Dr. Peter Schneider has served as National Principal Investigator for numerous clinical trials. He had also been the principle investigator of multiple DCB trials US, including the IN. PACT Admiral from Medtronic for SFA. Over 25 years, he has been a strong proponent of clinical research in vascular disease and has participated extensively in trial design, oversight, core lab analysis, events committees, data analysis, follow up, presentation, and publication. He has consulted on the regulatory pathway and pivotal trials for many vascular devices, has participated in numerous meetings with the FDA and has testified at FDA panel hearings. His experience includes performing procedures for several first-in-human trials.

The joining of Prof. Peter Schneider, Dr. Matthew T. Menard, Dr. Sahil A. Parikh, and Prof. Thomas Zeller will bring their strong experience and expertise in peripheral interventional area to accelerate the Company's global strategy and development of new products.

By order of the Board  
**Acotec Scientific Holdings Limited**  
**Jing LI**  
*Chairperson of the Board, Executive Director and  
Chief Executive Officer*

Hong Kong, October 10, 2021

*As at the date of this announcement, the executive Directors are Ms. Jing LI and Mr. Silvio Rudolf SCHAFFNER, the non-executive Directors are Mr. Ke TANG and Mr. Chen CHEN, and the independent non-executive Directors are Dr. Yuqi WANG, Ms. Hong NI and Ms. Kin Yee POON.*